IP Library Granted Patent US 10,611,826
Granted Patent B2
US 10,611,826 · App. 14/902,716 · Granted Apr 7, 2020

Affinity chromatography matrix

Inventors: Philippe Paolantonacci (Gif sur Yvette, FR); Abdessatar Chtourou (Elancourt, FR)
Assignee: Laboratoire Français du Fractionnement et des Biotechnologies
C07K16/065A61K39/39525B01D15/3804B01D15/3809B01J20/265B01J20/289B01J20/291B01J20/3219B01J20/3251B01J20/3255B01J20/3274C07K1/22C07K16/34B01J2220/80Y02P20/582
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,611,826
App. No.
14/902,716
Granted
Apr 7, 2020
Kind
B2
Abstract

The invention relates to an affinity chromatography matrix, as a gel, comprising polymeric particles on which at least one oligosaccharide corresponding to a blood group A epitope and/or blood group B is grafted, via a spacer, characterized in that the density of oligosaccharides is comprised between 0.2 and 0.7 mg/ml of matrix. The invention also relates to the uses of this matrix for preparing concentrates of immunoglobulins for therapeutic use.

Claims (27)

1. An affinity chromatography matrix, in form of a gel, comprising polymeric particles on which at least one oligosaccharide corresponding to a blood group A and/or group B epitope is grafted via a spacer, wherein:

the density of oligosaccharides is from about 0.3 to about 0.4 mg/ml of the matrix and

said spacer has a formula provided by

NH—R1-CO—NH—R2-  (I),

wherein R1 is a C 5 alkyl group, R2 is a C 3 alkyl group, and said spacer is bound through its amine function to the particle.

2. The matrix according to claim 1 , comprising (i) polymeric particles on which at least one oligosaccharide corresponding to a blood group A epitope is grafted, and/or (ii) polymeric particles on which at least one oligosaccharide corresponding to a blood group B epitope is grafted.

3. The matrix according to claim 2 , comprising (i) polymeric particles on which at least one oligosaccharide corresponding to a blood group A epitope is grafted, and (ii) polymeric particles on which at least one oligosaccharide corresponding to a blood group B epitope is grafted.

4. The matrix according to claim 1 , comprising polymeric particles on which both at least one oligosaccharide corresponding to a blood group A epitope and at least one oligosaccharide corresponding to a blood group B epitope, are grafted.

5. The matrix according to claim 1 , comprising a mixture of (i) polymeric particles on which at least one oligosaccharide corresponding to a blood group A epitope is grafted, (ii) polymeric particles on which at least one oligosaccharide corresponding to a blood group B epitope is grafted, and (iii) polymeric particles on which both at least one oligosaccharide corresponding to a blood group A epitope, and at least one oligosaccharide corresponding to a blood group B epitope, are grafted.

6. The matrix according to claim 1 , wherein the oligosaccharide corresponding to a blood group A epitope and/or the oligosaccharide corresponding to a blood group B epitope is a trisaccharide.

7. The matrix according to claim 6 , wherein the oligosaccharide corresponding to a blood group A epitope is a trisaccharide N-acetylgalactosamine (GalNAc)-Galactose (Gal)-Fucose.

8. The matrix according to claim 6 , wherein the oligosaccharide corresponding to a blood group B epitope is an oligosaccharide Galactose-Galactose-Fucose.

9. The matrix according to claim 3 , wherein the polymeric particles on which at least one oligosaccharide corresponding to a blood group A epitope is grafted, and the polymeric particles on which at least one oligosaccharide corresponding to a blood group B epitope is grafted, are mixed in a proportion of 25/75 to 75/25 (v/v), preferably about 50/50 (v/v).

10. The matrix according to claim 1 , wherein the polymer is a cross-linked polymer.

11. The matrix according to claim 10 , wherein the polymer is cellulose.

12. A method of using the matrix as defined in claim 1 , in an affinity chromatography binding anti-A and/or anti-B antibodies.

13. The method of using the matrix according to claim 12 , for producing on an industrial scale immunoglobulins G (IgG) for therapeutic use.

14. A process for preparing a concentrate of immunoglobulins G (IgG) for therapeutic use, comprising obtaining an Ig composition from blood plasma, by ethanol fractionation and/or caprylic fractionation and/or chromatographic separation, and subjecting the Ig composition to affinity chromatography using the matrix of claim 1 to remove the anti-A and/or anti-B antibodies from the Ig composition.

15. The matrix according to claim 1 , wherein the density of oligosaccharides is about 0.3 mg/ml of matrix.

16. The matrix according to claim 11 , wherein the particles are porous, cross-linked cellulose beads.

17. An affinity chromatography matrix, in form of a gel, comprising polymeric particles on which at least one oligosaccharide corresponding to a blood group A and/or group B epitope is grafted via a spacer, wherein:

the at least one oligosaccharide is a trisaccharide;

the density of oligosaccharides is from about 0.3 to about 0.4 mg/ml of the matrix;

said spacer has a formula provided by

NH—R1-CO—NH—R2-  (I),

wherein R1 is a C 5 alkyl group, R2 is a C 3 alkyl group, and said spacer is bound through its amine function to the particle; and

the particles are porous cross-linked cellulose beads.

Assignments (3)
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Apr 3, 2023
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 063237/0439 →
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Sep 21, 2022
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 061493/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2017
From: PAOLANTONACCI, PHILIPPE; CHTOUROU, ABDESSATAR
To: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 041081/0759 →
Priority Claims (2)
FR 13 56635 · Jul 5, 2013 · national
FR 13 56636 · Jul 5, 2013 · national
Continuity (1)
Related Publication 20160168229A1 · Jun 16, 2016
Cited By (1)
US 12,247,076